Advances in the treatment of autoimmune myositis
10.19845/j.cnki.zfysjjbzz.2025.0075
- VernacularTitle:自身免疫性肌炎治疗进展
- Author:
Bing ZHAO
1
;
Chuanzhu YAN
2
Author Information
1. 山东大学齐鲁医院（青岛）神经内科，山东 青岛 266035
2. 山东大学齐鲁医院（青岛）神经内科，山东 青岛 266035;山东省罕见病线粒体医学重点实验室，山东 济南 250012
- Publication Type:Journal Article
- Keywords:
Autoimmune myositis;
Interstitial lung disease;
Immunosuppressant;
Biologics;
Treatment advance
- From:
Journal of Apoplexy and Nervous Diseases
2025;42(5):387-394
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune myositis （AIM） is a group of autoimmune diseases that primarily affect muscle fibers， often accompanied by the involvement of multiple organs such as the skin，lungs，and joints.It is the most common treatable skeletal muscle disease in adults. Although most patients with AIM can achieve remission with traditional immunosuppressive therapies， their quality of life can be heavily reduced due to drug-related adverse effects and the high relapse rate and high disability rate of the disease. With the deepening understanding of the immunopathological mechanisms of AIM，various biologics targeting different components of these mechanisms have brought new hope for patients with AIM. This article reviews the advances in the treatment of AIM.
- Full text:2025071615263739134自身免疫性肌炎治疗进展.pdf
